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Abstract  
On red grouse estates in the UK the nematode parasite Trichostrongylus tenuis is often controlled 
by application of grit medicated with the anthelmintic fenbendazole (FBZ). To date, assessment of 
the efficacy has been inhibited by the inability to quantify uptake of FBZ by the birds. We have 
developed a simple and sensitive HPLC-MS-MS method for detecting and quantifying FBZ and its 
metabolites from a 300 mg sample of red grouse liver. This method could be used to improve the 
efficacy of medicated grit treatment by allowing the identification of conditions and application 
methods that optimize the uptake of FBZ. With the necessary modifications, our method will also 
be applicable to other wildlife species where self-medication is used for parasite control. 
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Introduction 1 
Medicated feed is frequently used for parasite control in wildlife populations, including red grouse 2 
(Newborn & Foster 2002), pheasants (Draycott et al., 2006) and bighorn sheep (Miller et al., 2000; 3 
Schmidt et al., 1979). Because these animals self-administer, drug uptake may vary among 4 
individuals and over time, for example due to differential access to feed. Assessment of drug uptake 5 
(and therefore efficacy), which is already difficult in self-administering populations, is hindered 6 
further by this variation. To aid parasite management in these situations, a reliable method to 7 
quantify drug uptake is required. 8 
 9 
One such approach is the quantification of drug residues in the tissues of harvested animals. Here 10 
we develop a quantification method for red grouse (Lagopus lagopus scoticus), an economically 11 
important game bird species endemic to the British Isles. Red grouse exhibit regular population 12 
collapses owing in part to high burdens of the parasitic nematode Trichostrongylus tenuis (Hudson 13 
et al., 1998). Control of these intestinal parasites helps reduce the frequency and severity of 14 
population crashes (Hudson et al., 1998). The most widespread technique for controlling T. tenuis 15 
in red grouse has been the provision of quartz grit, which grouse consume to aid digestion, coated 16 
with the anthelmintic drug fenbendazole (FBZ). Recently, the use of grit coated with flubendazole 17 
(FLUB), has also become widespread. Medicated grit piles are distributed on red grouse habitat in 18 
December and replenished in early March (Newborn and Foster, 2002). No medicated grit is 19 
distributed after the end of March (Intervet UK Ltd, Panacur Data Sheet), resulting in a minimal 20 
withdrawal period of 19 weeks to prevent FBZ residues (i.e. FBZ and its metabolites) from entering 21 
food products when grouse are harvested for human consumption from 12 August to 16 December. 22 
Treatment with FBZ-medicated grit has been shown to reduce average worm burdens by 34% 23 
(Newborn and Foster, 2002). 24 
 25 
FBZ is a member of the benzimidazole (BZ) group of anthelmintics which provides broad-spectrum 26 
efficacy against endoparasites and is widely used in domestic animals and humans (McKellar and 27 
Page 4 of 12 
Scott, 1990). Methods have been developed for the quantification of FBZ residues in liver, muscle 28 
and plasma from a range of domestic animals, including cattle, sheep and fish, using High 29 
Performance Liquid Chromatography (HPLC) or Liquid Chromatography–Mass Spectrometry 30 
(LC–MS) (Danaher et al., 2007). Here we present a method to quantify FBZ residues in red grouse 31 
livers using HPLC coupled to an ion trap tandem mass spectrometer (HPLC-MS-MS). We 32 
measured simultaneously FBZ and two of its metabolites, fenbendazole sulphone (FBZSO2) and 33 
oxfendazole (OFZ), plus an internal standard mebendazole (MBZ). Liver tissue was selected for 34 
analysis because it contains the highest total residue levels and is the tissue from which residues 35 
deplete most slowly (European Medicines Agency, 2004).  36 
 37 
The aims of this study were threefold: (1) to develop a simple and reliable method to quantify FBZ 38 
residues in grouse livers; (2) to assess variation in FBZ dosage among birds during treatment 39 
periods (December to March); and (3) to measure FBZ residue levels in samples from the shooting 40 
season (August 12 to December 10) in order to quantify residues entering food products.  41 
 42 
Materials and methods  43 
We obtained livers from 14 male red grouse aged at least 1 year from three grouse moors in the 44 
north of England, UK during August 2002 and March and August 2003 (Table 1). One moor was in 45 
Teesdale (TFBZ, n = 6) and two were in North Yorkshire (YFBZ, n = 5; YNEG, n = 3). Subscripts 46 
indicate history of benzimidazole treatment: TFBZ and YFBZ had 10 and 13 years, respectively, of 47 
consecutive treatment with FBZ-medicated grit prior to sampling while YNEG had never been 48 
treated, although situated adjacent to treated moors. The sampling dates of two YFBZ samples 49 
(August 2002) and two TFBZ samples (August 2003) fell within the shooting season, five months 50 
after drug treatment had ceased. Males more than one year old, and therefore likely to have had 51 
access to medicated grit treatments earlier in the year, were selected at random from the grouse 52 
harvested that day from each site. The remaining 10 samples were collected from dead birds outside 53 
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the shooting season in March 2003. These samples were taken opportunistically, and we have no 54 
information on self-medication frequency, dosage or proximity to medicated grit piles. We also 55 
cannot assume that sampling was representative. Nevertheless, as medicated grit piles were 56 
available to the grouse during this period, these samples were considered more likely to contain 57 
detectable residues than those collected in August. After collection, liver samples were frozen on 58 
dry ice (-78.5 °C) and transported to storage at -70 °C. Medicated grit was also collected from a grit 59 
pile in March 2003 and stored at -70 °C. 60 
 61 
Frozen liver samples were thawed and 300 mg subsamples were removed to 50 mL centrifuge 62 
tubes. To monitor variation introduced by the extraction procedure, two sub-samples were extracted 63 
from each liver and each was analysed separately. Control (drug negative) livers from the untreated 64 
site YNEG were selected for spiking with drug standards after we had checked that no detectable 65 
drug residues were present. Sample and control liver samples were fortified with 100 ng of the 66 
internal standard mebendazole (MBZ) to allow standardisation of recovery rates across HPLC-MS-67 
MS assays. Mean (±SD) recovery of the internal standard was 78 (±18) %. Control liver samples 68 
were also fortified with FBZ at a range of concentrations to allow validation of the method. The 69 
quantities added were 0, 0.05, 0.5, 5 and 50 ng, equivalent to 0, 0.167, 1.67, 16.7 and 167 µg kg-1 of 70 
liver.  71 
 72 
The residues to be quantified were FBZ and its metabolites oxfendazole (OFZ) and fenbendazole 73 
sulphone (FBZSO2) (Supplementary Figure 1). The presence of OFZ and FBZSO2 are indicative of 74 
FBZ intake (Danaher et al., 2007). FBZ, OFZ, FBZSO2 and MBZ were identified by their 75 
fragmentation pattern and by comparison of the peak retention times with that of previously run 76 
drug standards (Supplementary Figure 2). Each extraction was HPLC-MS-MS-analysed twice. The 77 
means of the resulting pair peak areas were interpolated onto calibration curves to calculate residue 78 
concentration in µg kg-1. A detailed description of the HPLC-MS-MS analysis is given in the 79 
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supplementary methods.  80 
 81 
Results  82 
FBZ was detected reliably in the three control livers: no FBZ was detected in either subsample from 83 
the negative control liver, and FBZ was detected in at least one subsample from each of the four 84 
spiked livers (Table 2). FBZ was also quantified accurately: measured concentration accurately 85 
reflected spiked concentration, as indicated by the closeness of the slope of the regression line to 86 
one (regression equation: ln measured concentration = 1.05 × ln spiked concentration; r2 = 0.986).  87 
The limit of detection (LOD) for FBZ was 0.17 µg kg-1, within the range reported in other studies 88 
using LCMS-MS (De Ruyck et al., 2002). The limits of quantification (LOQ) for all three residues 89 
were 0.7 µg kg-1 and 667 µg kg-1. 90 
 91 
FBZ or its metabolites OFZ and FBZSO2 were detected in eight of the eleven livers from the two 92 
FBZ-treated estates (Table 2) and none of the three livers from the untreated estate. Measured levels 93 
of FBZ averaged across each pair of subsamples ranged from below 0.17 µg kg-1 (the lower LOD) 94 
to 1.3 µg kg-1. Levels of OFZ ranged from 1.3–1916 µg kg-1 (median 29 µg kg-1), with the highest 95 
being values considerably above the LOQ of 667 µg kg-1. FBZSO2 ranged from 1.7–530 µg kg-1 96 
(median 13 µg kg-1). 97 
 98 
Among the eight birds where residues were detected — indicating exposure to FBZ — there was a 99 
strong tendency for the concentrations of both of the FBZ metabolites, OFZ and FBZSO2, to be 100 
higher than FBZ itself. This result agrees with data from sheep liver, where FBZ depleted ten times 101 
more quickly than OFZ over an 8 day period (Blanchflower et al., 1994). Levels of the three 102 
residues tended to covary. Log concentrations of OFZ and FBZSO2 were strongly positively 103 
correlated among the eight livers (r = 0.96, n = 8). Log concentrations of OFZ and FBZSO2 were 104 
also correlated with FBZ but less strongly (FBZ-OFZ r = 0.86, n = 4; FBZ-FBZSO2 r = 0.78, n = 105 
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4). From site YFBZ, the samples collected during the shooting season (YFBZ1–YFBZ2) tested positive 106 
for FBZ metabolites (Table 2), whereas the samples collected during the period of medicated grit 107 
treatment (Spring 2003) showed no detectable levels of FBZ or its metabolites. FBZ residues were 108 
generally at a higher level in March (during the treatment period) than in August (Table 2), 109 
although these differences were significant only for FBZ (P = 0.02, Wilcoxon rank sum test).  110 
 111 
No FBZ was found in the medicated grit sample, although its metabolites OFZ and FBZSO2 were 112 
detected at high levels relative to those observed in the liver samples (Table 2). The peak areas for 113 
these metabolites were above the LOQ, considerably so in the case of the active metabolite OFZ, 114 
and therefore the amount of active anthelmintic remaining of the 1000 µg kg-1 FBZ in fresh grit 115 
could not be quantified. 116 
117 
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Discussion 118 
When parasite control in free-living animals involves medicated grit or feed instead of direct drug 119 
application, managers need simple and efficient tools to monitor temporal and spatial variation in 120 
drug uptake. Our method for detecting the anthelmintic fenbendazole and its metabolites in liver 121 
tissue of game birds provides such a tool. The sensitivity of the method is demonstrated by the low 122 
LOD and by the detection of benzimidazole residues four months after the withdrawal of medicated 123 
grit piles. The lack of false positives among negative controls and samples from the untreated moor 124 
indicate high specificity. All but one of the pairs of replicate samples agreed in sensing the presence 125 
or absence of BZ residues, indicating that the technique is reliable but that running duplicate 126 
samples is advisable. The simplicity and speed of the method would allow it to be offered to estate 127 
managers at a cost that is low compared to the cost of treatment. 128 
 129 
Our method could also aid the prevention of the development of anthelmintic resistance. Since the 130 
pace and extent of anthelmintic resistance evolution is greatly affected by variation in drug dosage 131 
(Smith et al., 1999), managers should consider using the technique presented here to monitor 132 
individual variation in drug uptake to identify conditions and methods that delay the onset of drug 133 
resistance among the parasites for as long as possible. Our method may also be applicable to other 134 
game bird species such as pheasants (Draycott et al., 2006), and with the necessary modifications, 135 
to free-living mammals such as bighorn sheep (Miller et al., 2000; Schmidt et al., 1979) where 136 
medicated feeds are used and where drug uptake may vary greatly among individuals. 137 
 138 
Our study was based on samples collected from wild grouse for which we had no information on 139 
proximity to medicated grit piles, dosing frequency, length of time since the last dose, or how 140 
representative samples were of the grouse moor populations. Thus, the livers we analysed may 141 
therefore have been at different stages and levels of fortification. Despite these caveats, we found 142 
striking differences among birds in levels of the active anthelmintics FBZ and OFZ during the 143 
treatment period. FBZ was detected in only four of the seven samples taken from treated sites 144 
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during the treatment period (Table 2). Indeed, one of the treated sites (YFBZ) exhibited no 145 
measurable FBZ residues from any of the three birds sampled during the treatment period. These 146 
differences in residue level may reflect variation in the time since the last ingestion of medicated 147 
grit. However it is also possible that these differences reflect long term variation among birds in 148 
FBZ uptake caused by differential access to medicated grit piles in conjunction with territorial 149 
behaviour (Mougeot et al., 2003). Either way, our results suggest that there is substantial room for 150 
improvement to enable more birds to receive adequate FBZ dosage to control T. tenuis parasites.   151 
 152 
None of the four livers collected during the shooting season in August had any detectable FBZ, but 153 
FBZ metabolites tested were detected in all four of the samples. Maximum Residue Limits (MRLs) 154 
are established for anthelmintic residues in products for human consumption from most livestock 155 
species and these tend to be in the order of 10 µg kg-1 for milk and 500 µg kg-1 for liver in bovine, 156 
ovine, porcine and equine species (European Commission, 1990). The levels measured in our study 157 
are well below these limits, and therefore our data provide no evidence that the 19-week withdrawal 158 
period is insufficient to prevent human consumption of harmful levels of anthelmintic residues.  159 
 160 
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Tables 206 
Table 1. 207 
Details of medicated grit use and sample size for each site.  208 
Site FBZ grit use (years) 
Number of birds sampled 
Treatment period Hunting season Total 
TFBZ 10 4 2 6 
YFBZ 13 3 2 5 
YNEG None 3 0 3 
 209 
 210 
211 
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Table 2 Concentration (µg kg-1) of residues of fenbendazole (FBZ) and its metabolites oxfendazole 212 
(OFZ) and fenbendazole sulphone (FBZSO2) in eight red grouse livers collected from the BZ-213 
treated estates, TFBZ and YFBZ. Results are also shown from two samples of medicated grit and 5 214 
control livers spiked with FBZ. No residues were detected in an additional six livers collected in 215 
March 2003, three from YFBZ and three from the untreated estate YNEG (data not shown). ND: not 216 
detected. 217 
Sample ref. Sample date Sub-sample 
Residue concentration 
(µg kg-1) 
FBZ OFZ FBZSO2 
TFBZ1 Mar-03 A 0.8 2063* 486 
B 1.2 1770* 391 
TFBZ2 Mar-03 A 0.2* 1.9 1.6 
B 0.2* 1.1 1.7 
TFBZ3 Mar-03 A 1.1 863* 533 
B 1.5 833* 528 
TFBZ4 Mar-03 A 0.2* 78 165 
B 0.1* 103 92 
TFBZ5 Aug-03 A ND 1.4 2.5 
B ND 1.2 1.8 
TFBZ6 Aug-03 A ND 38 9.9 
B ND 65 15 
YFBZ1 Aug-02 A ND 2.2 1.4 
B ND 2.4 4.2 
YFBZ2 Aug-02 A ND 6.0 15 
B ND 5.6 12 
TFBZ  
(medigrit) 
Mar-03 A ND 16770* 1620* 
B ND 16592* 1168* 
FBZ-spiked 
(0 µg kg-1) 
- A ND - - 
B ND - - 
FBZ-spiked 
(0.17 µg kg-1) 
- A 0.10* - - 
B 0.099* - - 
FBZ-spiked 
(1.7 µg kg-1) 
- A 0.89 - - 
B 1.1 - - 
FBZ-spiked 
(17 µg kg-1) 
- A 17 - - 
B ND - - 
FBZ-spiked 
(167 µg kg-1) 
- A 175 - - 
B 256 - - 
*Concentration outside limits of quantification (0.7–667 µg kg-1) 218 
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Supplementary material 
Quantifying fenbendazole and its metabolites in self-medicating wild red grouse Lagopus 
lagopus scoticus using an HPLC-MS-MS approach 
Aileen Adam, Lucy M. I. Webster, William Mullen, Lukas F. Keller, Paul C. D. Johnson 
 
Supplementary methods 
Subsamples of 300 mg of each liver were allowed to stand for 30 min before being frozen at -70 ºC 
prior to freeze-drying for 36-48 hr. On removal samples were homogenised with a mortar and pestle 
and dry weights were taken. The standard deviation of the dry weights of the samples was 13% of 
the mean. Methanol (20 mL) was added to the ground tissue and each sample was vortexed for 5 
min before centrifugation at 4000 rpm for 20 min at 4 °C in a cooling centrifuge. The supernatant 
was removed and partitioned with an equal volume of hexane. Partitioning was repeated before the 
methanol portion was removed to a quick-fit flask and evaporated to dryness using a rotary 
evaporator. The dried residue was resuspended in 1 mL methanol and vortexed. Samples were 
centrifuged in a sample concentrator for 1 hr 30 min and the pellet resuspended in 100 µl methanol. 
The extractions were centrifuged for a further 30 min at 13000 rpm to remove any remaining 
impurities. Finally, the purified supernatant was removed and used for HPLC-MS-MS analysis. 
Medicated grit samples were extracted in the same way as livers, with the exception that 1 g of grit 
was used. 
 Samples were analysed on a Surveyor HPLC system comprising of a HPLC pump, diode 
array absorbance detector, scanning from 250 to 700 nm and an autosampler cooled to 4°C. HPLC 
separation was carried out using a 4 µm, 250 × 2.0 mm i.d. Synergi RP-Max column with a 2-mm 
guard column maintained at 65 ºC, eluted with a gradient over 30 min of 25-55% acetonitrile in 
0.1% formic acid at a flow rate of 200 mL/min and maintained at 65 °C. After passing through the 
flow cell of the diode array detector the column eluate was directed to an LCQ Advantage ion trap 
mass spectrometer fitted with an electrospray interface controlled by Xcalibur software version 1.2. 
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Analyses utilized the positive ion mode as this provided the best limits of detection. Analysis was 
performed using selected reaction monitoring carried out over 3 segments. For segment 1 from 0 to 
14 min the parent ion at m/z 316 was fragmented with a relative collision energy of 35% and the 
product ions scanned from m/z 125 to 316. For segment 2 from 14.1 to 23.5 min the parent ions 
were m/z 296 and 332, the relative collision energy was 35%, and the product ions scanned from 
m/z 125 to 296 and m/z 125 to 332 respectively. For segment 3 from 23.6 to 30 min the parent ion 
was m/z 300, relative collision energy 35% and product ions scanned from m/z 125 to 300. In all 
cases the ion chosen for quantification was the fragment ion [M-32+H]+ resulting from the loss of 
CH3O (Supplementary Figure 1). As mebendazole and fenbenzadole sulphone elute within 2 
minutes of each other, we used a single segment (segment 2) to facilitate integration of the peaks.  
Capillary temperature was 275 °C, sheath gas and auxiliary gas were 40 and 10 units respectively 
and source voltage was 4.5 kV.  
Solvents used were HPLC grade methanol, hexane and acetonitrile (Rathburn Chemicals 
Ltd), and analytical grade formic acid (Fisher Scientific UK). The analytical standards were FBZ, 
oxfendazole (QMX Laboratories Limited), fenbendazole sulphone (kindly donated by Intervet 
International) and HPLC grade dimethyl sulfoxide (Sigma-Aldrich Company Ltd), and the internal 
standard was mebendazole (Sigma-Aldrich Company Ltd). All water used was of HPLC grade. 
Stock standard solutions of FBZ, OFZ, FBZSO2 and internal standard mebendazole (MBZ) 
were prepared at a concentration of 1 mg mL-1 in dimethyl sulfoxide + methanol (9/1, v/v). The 
internal standard was chosen due to its structural similarities to the compound under investigation 
and was used to control for extraction, HPLC and ionization variability. These solutions were stored 
at 5 ºC and showed no significant changes after one month, when they were replaced by fresh 
solutions. Working standard solutions were prepared at concentrations ranging from 5–50,000 ng 
mL-1 by dilution with dimethyl sulfoxide + methanol (9/1, v/v). A standard solution, 100 ng mL-1 
was used for tuning the mass spectrometer. Linear calibration curves were generated by plotting 
ln(peak area) against ln(working standard solution concentration). r2-values for the calibration 
curves were 0.99806 (MBZ), 0.99998 (FBZ), 0.99833 (OFZ) and 0.99983 (FBZSO2). 
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FBZ, OFZ, FBZSO2 and MBZ were identified by their fragmentation pattern and by 
comparison of the peak retention times with that of previously run drug standards (Supplementary 
Figure 2). The four compounds under investigation all displayed a characteristic loss of CH3O in 
the MS-MS spectra with no other significant ions being produced. The absence of any other ions in 
the MS-MS spectrum was used as additional proof of compound identity and peak purity. The use 
of Selected Reaction Monitoring using an ion trap mass spectrometer allows confirmation of the 
peak under investigation, by providing the full fragmentation spectra of the parent ion, without a 
loss of sensitivity. Only the major fragment ion formed from each parent was used in quantification. 
The limit of detection (LOD) was determined at a signal to noise ratio of 3, as reported by 
the Xcalibur peak integration software and quantification was carried out on peaks that had a signal 
to noise ratio greater than 9. No false positive peaks were detected for any of the four compounds 
under investigation during the course of the study. Tissue drug residue concentration in µg kg-1 
(ppb) was calculated from sample drug concentrations (estimated from the calibration curve), 
sample solution volume and sample weight. Mean (±SD) recovery of the internal standard was 78 
(±18) %; where recovery was less than 100%, residue concentration was adjusted by dividing by 
the recovery fraction. 
The extraction method used in this analysis is much quicker and simpler than any reported 
for similar compounds (Danaher et al., 2007). Although the lack of clean up stages could result in 
more contaminants in the extract, no interfering peaks or false positives were seen in the analysis. 
The sensitivity and selectivity of the analysis allowed sample weights to be reduced to only 300 mg 
of liver. The low variation in the dry weights of these samples suggests that 300 mg samples can be 
weighed with a sufficient degree of accuracy for detection and quantification. However, it is likely 
that the accuracy of quantification would be further improved by increasing the sample weight. 
Reference 
Danaher, M., De Ruyck, H., Crooks, S.R.H., Dowling, G., O'Keeffe, M., 2007. Review of 
methodology for the determination of benzimidazole residues in biological matrices. J. 
Chromatogr. B 845, 1-37. 
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Supplementary Figure 1  Molecular structures of the benzimidazoles investigated in this study. 
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Supplementary Figure 2  Chromatograms of analytical standards (I) and a liver sample taken from 
sample T+6B (see Table 2) (II). A: absorbance at 290 nm. B: SRM m/z 298 > m/z 266 
(mebendazole I.S.) C:  SRM m/z 302 > m/z 270 (Fenbendazole). D: SRM m/z 318 > m/z 286 
(oxfendazole.). E: SRM m/z 334 > m/z 302 (fenbendazole) sulphone. 
